The Emergence of B7-H3 Antibody-Drug Conjugates for the Treatment of Relapsed Small Cell Lung Cancer (SCLC) With a Review of the IDeate-Lung02 Clinical Trial

Video content above is prompted by the following:

1. Please discuss the unique mechanism of action of B7-H3 and its treatment potential as a subsequent therapy for SCLC, which has progressed after platinum-based chemotherapy.
2. Is individual B7-H3 analysis currently available at your institution?
3. Please share your impressions of the efficacy outcomes reported in IDeate-Lung02: 52.4% overall response rate, a 5.9-month median duration of response, and a 12.2-month OS.
   1. How clinically meaningful do you consider a 12-month OS in this study population after a median of 2 prior lines of therapy?
4. In terms of simplicity, treatment compliance, and quality of life, how does the dosing schedule of ifinatamab deruxtecan compare with those of topotecan and lurbinectedin?
5. In your opinion, what treatment synergies might you expect from a
   combination of MK-6070, the tri-specific T-cell engager, and ifinatamab
   deruxtecan?
   1. At this stage in early clinical development, which patient and/or disease factors might persuade you to consider dual T-cell engager therapy?
6. Given the currently available data on ifinatamab deruxtecan, please evaluate its potential in combination with atezolizumab with or without platinum-based chemotherapy as first-line induction or maintenance therapy in ES-SCLC.
   1. What would you consider to be statistically significant end points with dual or triple therapy to warrant clinical application in this patient population?